Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2024-09-12 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific business event: a license agreement between Sanofi, RadioMedix, and Orano Med regarding the development of a new radiopharmaceutical (AlphaMedix™). It details the terms of the agreement, quotes executives, provides background information on the disease (Neuroendocrine Tumors), and includes standard forward-looking statements and contact information typical of a corporate announcement. This format strongly indicates an initial public announcement of a significant corporate event, which aligns best with an Earnings Release (ER) if it were financial results, but since it is a strategic partnership/licensing deal announcement, it is most closely categorized as a general corporate announcement. Given the options, and since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate general category for a major corporate news announcement that isn't strictly financial results is often the Earnings Release category if it contains material business updates, or RNS if it's a general regulatory filing. However, because it is a detailed press release announcing a major strategic deal (licensing, financial terms mentioned), it functions as a key business update. In many databases, major strategic announcements that are not quarterly results fall under a general news/regulatory category. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is not financial results, the best fit among the specific options for a major, non-financial corporate announcement is often the general Regulatory Filings (RNS) category, or potentially a specific M&A/Partnership category if one existed. Since this is a press release announcing a major licensing deal, and it is not a formal SEC filing like 10-K or a specific report, RNS (Regulatory Filings / miscellaneous announcements) is the most suitable fallback for significant, non-standard corporate news.
2024-09-12 French
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Earnings Release Classification · 100% confidence The document is explicitly titled and formatted as a "Press Release" announcing positive Phase 3 clinical trial results for the drug Dupixent in treating Chronic Spontaneous Urticaria (CSU). It contains key financial/operational news (drug trial success, regulatory plans, executive quotes) but is not a comprehensive annual report (10-K), a detailed interim report (IR), or a transcript (CT). It is an initial announcement of results, which aligns best with the definition of an Earnings Release (ER) as it communicates key performance/development milestones, even though it is not strictly quarterly earnings. However, given the specific focus on clinical trial data and regulatory updates rather than financial performance highlights, it functions as a major corporate announcement. Since 'Earnings Release' (ER) is often used broadly for major operational announcements, and there isn't a specific 'Clinical Trial Result Announcement' code, ER is the closest fit among the provided options for a time-sensitive, high-impact corporate announcement. It is definitely not a Report Publication Announcement (RPA) because it contains the full substance of the news, not just a notice that a report is available. Q3 2024
2024-09-11 English
Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée
Earnings Release Classification · 92% confidence The document is titled "Communiqué de presse" (Press Release) and details positive Phase III clinical trial results (LIBERTY-CUPID Study C) for the drug Dupixent in treating Chronic Spontaneous Urticaria (CSU). It includes quotes from Chief Medical Officers and discusses future regulatory submissions (FDA submission planned by year-end). This format—announcing significant clinical trial data and business/regulatory milestones via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on announcing key results rather than just announcing the publication of a report (RPA), the most appropriate classification is Earnings Release (ER), as press releases often accompany or substitute for formal earnings highlights, especially when announcing clinical trial breakthroughs that impact future revenue/outlook. Given the context of pharmaceutical news, ER is often used for major data readouts that drive investor sentiment, even if not strictly tied to quarterly earnings figures in this specific text snippet. Q3 2024
2024-09-11 French
Communiqué de presse : Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients
Regulatory Filings Classification · 95% confidence The document is a press release ("Communiqué de presse") detailing positive results from a pivotal clinical study (ADEPT) for the drug Dupixent in treating Bullous Pemphigoid (PB). It includes efficacy data, safety profiles, quotes from medical officers, and details about the study design. This type of announcement, which releases key clinical trial results and discusses regulatory submission plans ("Cette étude soutiendra les soumissions réglementaires dans le monde entier"), is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a detailed announcement of financial/operational results (clinical trial success), and not a transcript (CT), a formal annual report (10-K), or a short notice of report publication (RPA), the most fitting category is Earnings Release (ER), as these often contain significant operational/pipeline updates alongside financial reporting, or sometimes, if purely scientific, it might lean towards a Regulatory Filing (RNS). Given the structure and purpose (announcing major positive trial data to the market), ER is the best fit among the provided options, as it communicates key performance indicators (trial success) that impact the company's outlook. It is not a formal regulatory filing like a 10-K or a short RPA.
2024-09-11 French
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and details the positive results of a pivotal clinical study (ADEPT) for the drug Dupixent in treating bullous pemphigoid (BP). It includes key efficacy data, safety information, quotes from management, and outlines future regulatory submission plans ("This study will support regulatory submissions around the world, starting with the U.S. later this year."). This format—a formal announcement of clinical trial results intended for immediate public dissemination—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing significant clinical trial data, it is best classified as an Earnings Release (ER) as these often include major operational or clinical milestones alongside financial updates, or as a general Regulatory Filing (RNS) if it strictly pertains only to clinical data without financial performance highlights. Given the focus on trial results and regulatory next steps, and the lack of explicit quarterly financial figures (like revenue or EPS), it fits best under the general category for significant, non-standardized announcements, which is RNS, or ER if we interpret clinical trial success as a major operational update. However, ER is typically for periodic financial results. Since this is a specific announcement of clinical trial success that will support future regulatory submissions, and it is not a transcript, a formal report (10-K/IR), or a management discussion (MDA), the most appropriate category for a major, non-periodic operational/clinical announcement that isn't a formal report is RNS (Regulatory Filings/General Announcement). If the document were focused purely on financial performance metrics, ER would be better. Given the context of clinical trial success leading to regulatory filings, RNS is the safest fit as a broad regulatory announcement.
2024-09-11 English
Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône
Regulatory Filings Classification · 92% confidence The document is titled "Communiqué de presse" (Press Release) and announces the inauguration of a new, revolutionary modular vaccine and biopharmaceutical manufacturing plant by Sanofi, detailing the investment (€500 million), capacity, and strategic importance. It includes quotes from the CEO and contact information for media relations. This type of announcement, focusing on a significant corporate event (a major capital investment and facility opening) released to the public via a press release format, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). While it discusses investment, it is not a formal Capital/Financing Update (CAP) which usually details fundraising or debt issuance. It is a general corporate announcement. Given the options, the most appropriate general category for a significant, non-standard regulatory or financial announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous official announcements, although 'Press Release' is not an explicit option. However, since it is a formal announcement of a major corporate development, and not a report itself, RNS is the best fit among the provided codes for a general corporate news release.
2024-09-10 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.